(R)-1-(4-chlorobenzyl)-5-(pyrrolidin-2-yl)-1H-tetrazole | 1140496-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-(4-chlorobenzyl)-5-(pyrrolidin-2-yl)-1H-tetrazole
• 英文别名: 1-[(4-chlorophenyl)methyl]-5-[(2R)-pyrrolidin-2-yl]tetrazole
• CAS: 1140496-49-6
• 化学式: C₁₂H₁₄ClN₅
• 分子量: 263.73
• InChiKey: HBYUVXMFPCAOPJ-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-1-(4-chlorobenzyl)-5-(pyrrolidin-2-yl)-1H-tetrazole 、 4-三氟甲基苯基异氰酸酯 在 N,N-二异丙基乙胺 作用下， 以91%的产率得到(R)-2-(1-(4-chlorobenzyl)-1H-tetrazol-5-yl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-1-carboxamide
  参考文献：
  名称：

  ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION

  摘要：

  公式为的化合物已被披露。这些化合物是CCR1拮抗剂，可用于治疗和预防炎症性和自身免疫性疾病。其他实施例也已披露。

  公开号：

  US20090093472A1
• 作为产物：
  描述：

  (R)-benzyl 2-(1-(4-chlorobenzyl)-1H-tetrazol-5-yl)pyrrolidine-1-carboxylate 在 碘代三甲硅烷 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以31%的产率得到(R)-1-(4-chlorobenzyl)-5-(pyrrolidin-2-yl)-1H-tetrazole
  参考文献：
  名称：

  Novel pyrrolidine heterocycles as CCR1 antagonists

  摘要：

  A novel series of pyrrolidine heterocycles was prepared and found to show potent inhibitory activity of CCR1 binding and CCL3 mediated chemotaxis of a CCR1-expressing cell line. A potent, optimized triazole lead from this series was found to have acceptable pharmacokinetics and microsomal stability in rat and is suitable for further optimization and development. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.082

文献信息

• ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION
  申请人：Paradkar Vidyadhar M.

  公开号：US20090093472A1

  公开（公告）日：2009-04-09

  Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

  公式为的化合物已被披露。这些化合物是CCR1拮抗剂，可用于治疗和预防炎症性和自身免疫性疾病。其他实施例也已披露。
• US8288371B2
  申请人：——

  公开号：US8288371B2

  公开（公告）日：2012-10-16
• [EN] ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION<br/>[FR] ANTAGONISTES DE CCR1 HÉTÉROCYCLIQUES À SUBSTITUTION BENZYLIQUE D'ORTHO-PYRROLIDINE POUR LES MALADIES AUTO-IMMUNES ET L'INFLAMMATION
  申请人：PHARMACOPEIA INC

  公开号：WO2009082526A2

  公开（公告）日：2009-07-02

  Compounds of the formula (I) are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.
• Novel pyrrolidine heterocycles as CCR1 antagonists
  作者：J. Robert Merritt、Ray James、Vidyadhar M. Paradkar、Chongwu Zhang、Ruiyan Liu、Jinqi Liu、Biji Jacob、Camelia Chiriac、Michael J. Ohlmeyer、Elizabeth Quadros、Pamela Wines、Jennifer Postelnek、Catherine M. Hicks、Weiqing Chen、Earl F. Kimble、Linda O’Brien、Nicole White、Hema Desai、Kenneth C. Appell、Maria L. Webb

  DOI：10.1016/j.bmcl.2010.07.082

  日期：2010.9

  A novel series of pyrrolidine heterocycles was prepared and found to show potent inhibitory activity of CCR1 binding and CCL3 mediated chemotaxis of a CCR1-expressing cell line. A potent, optimized triazole lead from this series was found to have acceptable pharmacokinetics and microsomal stability in rat and is suitable for further optimization and development. (c) 2010 Elsevier Ltd. All rights reserved.